Literature DB >> 8388200

Mechanism of action of quinolones against Escherichia coli DNA gyrase.

H Yoshida1, M Nakamura, M Bogaki, H Ito, T Kojima, H Hattori, S Nakamura.   

Abstract

The mechanism of action of quinolones was investigated by use of various DNA gyrases reconstituted from wild-type and mutant GyrA and GyrB proteins of Escherichia coli. The quinolone sensitivities of the DNA supercoiling activity of the gyrases were generally parallel to the quinolone susceptibilities of strains having the corresponding enzymes and depended on gyrase subunits but not on substrate DNA. [3H]Enoxacin did not bind to gyrase alone or DNA alone but bound to gyrase-DNA complexes when measured by a gel filtration method. There appeared to be two enoxacin binding phases, at low and high enoxacin concentrations, for the wild-type gyrase-DNA and type 2 GyrB (Lys-447 to Glu) mutant gyrase-DNA complexes but only one enoxacin binding phase at the concentrations used for the GyrA (Ser-83 to Leu) mutant gyrase-DNA and type 1 GyrB (Asp-426 to Asn) mutant gyrase-DNA complexes. New enoxacin binding sites appeared in the presence of enoxacin, and the enoxacin binding affinities for the sites, especially at low enoxacin concentrations, near the MICs for the strains having the corresponding gyrases, correlated well with the enoxacin sensitivities of the gyrases and the MICs. From the results obtained, we propose a quinolone pocket model as the mechanism of action of quinolones, in which quinolones exert their action through binding to a gyrase-DNA complex and the quinolone binding affinities for the complex are determined by both GyrA and GyrB subunits in concert.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8388200      PMCID: PMC187778          DOI: 10.1128/AAC.37.4.839

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS.

Authors:  G Y LESHER; E J FROELICH; M D GRUETT; J H BAILEY; R P BRUNDAGE
Journal:  J Med Pharm Chem       Date:  1962-09

2.  DNA gyrase: purification and catalytic properties of a fragment of gyrase B protein.

Authors:  M Gellert; L M Fisher; M H O'Dea
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

3.  Quinolone antibacterial agents. Oxolinic acid and related compounds.

Authors:  D Kaminsky; R I Meltzer
Journal:  J Med Chem       Date:  1968-01       Impact factor: 7.446

4.  A rapid boiling method for the preparation of bacterial plasmids.

Authors:  D S Holmes; M Quigley
Journal:  Anal Biochem       Date:  1981-06       Impact factor: 3.365

Review 5.  DNA topoisomerases.

Authors:  M Gellert
Journal:  Annu Rev Biochem       Date:  1981       Impact factor: 23.643

6.  Deoxyribonucleic acid gyrase-deoxyribonucleic acid complex containing 140 base pairs of deoxyribonucleic acid and an alpha 2 beta 2 protein core.

Authors:  L Klevan; J C Wang
Journal:  Biochemistry       Date:  1980-11-11       Impact factor: 3.162

7.  Escherichia coli mutants thermosensitive for deoxyribonucleic acid gyrase subunit A: effects on deoxyribonucleic acid replication, transcription, and bacteriophage growth.

Authors:  K N Kreuzer; N R Cozzarelli
Journal:  J Bacteriol       Date:  1979-11       Impact factor: 3.490

8.  Purification of subunits of Escherichia coli DNA gyrase and reconstitution of enzymatic activity.

Authors:  N P Higgins; C L Peebles; A Sugino; N R Cozzarelli
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

9.  DNA gyrase: subunit structure and ATPase activity of the purified enzyme.

Authors:  K Mizuuchi; M H O'Dea; M Gellert
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

10.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

View more
  42 in total

1.  In vitro characterization of DNA gyrase inhibition by microcin B17 analogs with altered bisheterocyclic sites.

Authors:  D B Zamble; D A Miller; J G Heddle; A Maxwell; C T Walsh; F Hollfelder
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

2.  Inhibition of Escherichia coli viability by external guide sequences complementary to two essential genes.

Authors:  J McKinney; C Guerrier-Takada; D Wesolowski; S Altman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

3.  Alterations in GyrA and ParC associated with fluoroquinolone resistance in Enterococcus faecium.

Authors:  N A el Amin; S Jalal; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

4.  Cloning and sequencing of a novel gene (recG) that affects the quinolone susceptibility of Staphylococcus aureus.

Authors:  T Niga; H Yoshida; H Hattori; S Nakamura; H Ito
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

5.  parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.

Authors:  Kendal M Galbraith; Amanda C Ng; Betsy J Eggers; Craig R Kuchel; Christian H Eggers; D Scott Samuels
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

6.  Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.

Authors:  Jacob Strahilevitz; Ari Robicsek; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

7.  Exceptional convergent evolution in a virus.

Authors:  J J Bull; M R Badgett; H A Wichman; J P Huelsenbeck; D M Hillis; A Gulati; C Ho; I J Molineux
Journal:  Genetics       Date:  1997-12       Impact factor: 4.562

8.  Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus.

Authors:  M Tanaka; Y Onodera; Y Uchida; K Sato
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.

Authors:  P Heisig
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

Review 10.  Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance.

Authors:  David C Hooper; George A Jacoby
Journal:  Cold Spring Harb Perspect Med       Date:  2016-09-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.